Noven
Executive Summary
Transdermal estradiol patch is "approvable" at FDA, firm announces March 25. The 3-1/2 day patch is pending in four strengths: .0375, .05, .075 and 1 mg/day. Ciba-Geigy has rights to the product under a November 1991 agreement. Noven filed the NDA for the patch in December 1992
Transdermal estradiol patch is "approvable" at FDA, firm announces March 25. The 3-1/2 day patch is pending in four strengths: .0375, .05, .075 and 1 mg/day. Ciba-Geigy has rights to the product under a November 1991 agreement. Noven filed the NDA for the patch in December 1992. |